Xponance Inc. Cuts Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Xponance Inc. lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.8% during the second quarter, HoldingsChannel.com reports. The firm owned 17,762 shares of the biopharmaceutical company’s stock after selling 1,101 shares during the period. Xponance Inc.’s holdings in Halozyme Therapeutics were worth $930,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 254 shares during the period. Rise Advisors LLC purchased a new position in Halozyme Therapeutics during the first quarter valued at $25,000. International Assets Investment Management LLC purchased a new position in Halozyme Therapeutics during the second quarter valued at $33,000. Whittier Trust Co. acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at about $27,000. Finally, Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Halozyme Therapeutics during the second quarter worth about $49,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the sale, the chief executive officer now owns 676,744 shares in the company, valued at $40,063,244.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total value of $592,000.00. Following the transaction, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $40,063,244.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $53.93, for a total transaction of $269,650.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares of the company’s stock, valued at approximately $834,836.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 84,881 shares of company stock worth $4,932,284. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 0.0 %

Shares of HALO opened at $56.97 on Friday. Halozyme Therapeutics, Inc. has a 12-month low of $32.83 and a 12-month high of $65.53. The firm has a market capitalization of $7.25 billion, a P/E ratio of 23.54, a P/E/G ratio of 0.56 and a beta of 1.28. The firm has a 50-day moving average price of $58.67 and a 200 day moving average price of $49.68. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.18. The business had revenue of $231.40 million during the quarter, compared to analysts’ expectations of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.68 EPS. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Benchmark reaffirmed a “buy” rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. HC Wainwright reissued a “buy” rating and issued a $65.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, September 13th. Morgan Stanley lifted their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, TD Cowen increased their target price on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.